James Aloysius Brady - 14 Mar 2022 Form 4 Insider Report for Verona Pharma plc (VRNA)

Role
Director
Signature
/s/ Claire Poll, Attorney-in-fact for James Aloysius Brady
Issuer symbol
VRNA
Transactions as of
14 Mar 2022
Net transactions value
$0
Form type
4
Filing time
16 Mar 2022, 06:04:18 UTC
Next filing
28 Apr 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRNA Share Options (Right to Buy) Award $0 +288,000 $0.000000 288,000 14 Mar 2022 Ordinary Shares 288,000 $0.6025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2 The option vests and becomes exercisable as to 25% on August 1, 2022, 25% on November 1, 2022, 25% on February 1, 2023 and 25% on May 1, 2023.